Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers

Innate Immunity

Volumn 14, Issue 6, 2008, Pages 383-394

  Rossignol, Daniel P ^a   Wong, Nancy ^b   Noveck, Robert ^c   Lynn, Melvyn ^a  

^a EISAI INC   (United States)

^b Research Institute   (United States)

^c MDS Inc   (Canada)

Author keywords

Antagonist; Clinical research; Endotoxin; Sepsis; Toll like receptor 4

Indexed keywords

ERITORAN; LIPOPOLYSACCHARIDE; PLACEBO; DRUG DERIVATIVE; LIPID A; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FEVER; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECCHYMOSIS; FEMALE; FLATULENCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; PHARMACODYNAMICS; PHARYNGITIS; PHLEBITIS; SEX DIFFERENCE; SIDE EFFECT; VASODILATATION; DRUG ANTAGONISM; ENDOTOXEMIA; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE;

ANIMALIA;

DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTOXEMIA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LIPID A; LIPOPOLYSACCHARIDES; MALE; METABOLIC CLEARANCE RATE; PHLEBITIS; TOLL-LIKE RECEPTOR 4;

EID: 58949088145     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425908099173     Document Type: Article

References (19)

1. Rossignol DP, Lynn M. Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002; 8: 483-488.
2. Rossignol DP, Lynn M. TLR4 antagonists for endotoxemia and beyond. Curr Opin Invest Drugs 2005; 6: 496-502.
3. Rossignol DP, Christ WJ, Hawkins LD et al. Synthetic Endotoxin Antagonists. In: Brade H, Opal SM, Vogel SN, Morrison DC. (eds) Endotoxin in Health and Disease. New York: Marcel Dekker, 1999; 699-718.
4. Mullarkey M., Rose JR, Bristol J. et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-1102.
5. Poltorak A., He X., Smirnova I. et al. Defective LPS signaling in C3H/ HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-2088.
6. Du X., Poltorak A., Silva M., Beutler B. Analysis of TLR4-mediated LPS signal transduction in macrophages by mutational modification of the receptor. Blood Cells Mol Dis 1999; 25: 328-338.
7. Wong YN, Rossignol D., Rose JR, Kao R., Carter A., Lynn M. Safety, pharmacokinetics and pharmacodynamics of E5564, a lipid A antagonist, during an ascending single-dose clinical study. J Clin Pharmacol 2003; 43: 735-742.
8. Suganuma A., Rossignol DP, Kaneko K., LaRochelle AW, Kerns WD Clinical pharmacology of E5564, a lipid A antagonist, in a canine lipopolysaccharide challenge model. J Endotoxin Res 2000; 6: 115.
9. Rossignol DP, Wasan KM, Choo E. et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of Eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004; 48: 3233-3240.
10. Rose JR, Mullarkey MA, Christ WJ et al. Consequences of interaction of a lipophilic endotoxin antagonist with plasma lipoproteins. Antimicrob Agents Chemother 2000; 44: 504-510.
11. Lynn M., Wong YN, Wheeler JL et al. Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia corrected. J Pharmacol Exp Ther 2004; 308: 175-181.
12. Lynn M., Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631-639.
13. Rose JR, Christ WJ, Bristol JR, Kawata T., Rossignol DP Agonistic and antagonistic activities of bacterially derived Rhodobacter sphaeroides lipid A: Comparison with activities of synthetic material of the proposed structure and analogs. Infect Immun 1995; 63: 833-839.
14. Hermann C., von Aulock S., Dehus O. et al. Endogenous cortisol determines the circadian rhythm of lipopolysaccharide- but not lipoteichoic acid-inducible cytokine release. Eur J Immunol 2006; 36: 371-379.
15. Akashi S., Saitoh S.-i, Wakabayashi Y. et al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: Higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198: 1035-1042.
16. Visintin A., Halmen KA, Latz E., Monks BG, Golenbock DT Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol 2005; 175: 6465-6472.
17. Opal SM, Scannon PJ, Vincent JL et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180: 1584-1589.
18. Northoff H., Flegel WA, Yurttas R., Weinstock C. The role of lipoproteins in the inactivation of endotoxin by serum. Infusionsther Transfusionsmed 1992; 19: 202-203.
19. Hubsch AP, Casas AT, Doran JE Protective effects of reconstituted high-density lipoprotein in rabbit Gram-negative bacteremia models. J Lab Clin Med 1995; 126: 548-558.